R&D Non-opioid painkillers: Another tool to fight the opioid epi... The opioid epidemic is still an ongoing problem and there is no single solution to bring it under control.
News Lilly cuts $1bn deal for Centrexion’s non-opioid painkiller Eli Lilly has signed another bolt-on deal to bulk up its pipeline, this time paying $47.5 million upfront for rights to a non-opioid analgesic drug developed by US biotech Centrexion Therap
News Quartet of biotechs join Nasdaq after stellar IPOs Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
